Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Next-Gen Cell Therapy Starts with the Right T Cells
4+ hour, 35+ min ago (521+ words) August 19, 2026 | Wednesday | Influencers | By Ankit Kankar | [email protected] CD8+ T cells are often described as the immune system's "executioners". What advantages do they offer over CD3+ T cells in the development of next-generation cell therapies? CD3+ T cells have been used successfully as…...
BioArctic expands BrainTransporter platform from neurodegeneration to glioblastoma with Mesenkia collaboration
4+ hour, 12+ min ago (328+ words) AllSci Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and preclinical-stage Mesenkia Therapeutics have signed a research collaboration agreement to generate a novel antibody-based candidate for glioblastoma, marking BioArctic's first move into oncology with its BrainTransporter blood-brain barrier (BBB) delivery platform. Financial…...
Your Gut Cells Can "Forget" What They Are to Repair Damage, and Colon Tumors Steal the Same Switch
5+ hour, 1+ min ago (784+ words) Biology textbooks tend to describe cell identity as a one-way trip. A stem cell becomes a specialized cell, and that is the end of the story. The lining of the human intestine has never fully obeyed that rule, and researchers…...
Helping bones heal: Researchers turn lab discovery into startup
3+ hour, 43+ min ago (122+ words) Today, Vega serves as CEO, Kim serves as chief medical officer, and Rowan alumnus Matthias Recktenwald, Ph.D., serves as chief scientific officer, leading peptide discovery and preclinical development efforts. While bone healing remains the company's primary focus, HydroPep's broader vision…...
AI Model Boosts Digital Coaching, Rehab
9+ hour, 18+ min ago (267+ words) New AI model could improve digital coaching and rehab A novel AI system capable of recognising yoga poses with high accuracy could pave the way for more effective digital coaching tools, rehab platforms and movement-monitoring applications. A new study, co-authored…...
New Computational Tool Identifies Previously Hidden Asthma Genes
41+ min ago (385+ words) Aug 19, 2026 | Asthma An interdisciplinary team of researchers at UChicago and Columbia University developed a new computational tool to identify genes most directly related to asthma, according to a study published in Cell. The tool, known as Dandelion, identifies central genes…...
CCCC celebrates opening of E. Eugene Moore Center biotech facility
1+ hour, 11+ min ago (13+ words) The Sanford Herald...
Regeneron halts first-in-human REGN7041 trial after safety event
3+ hour, 33+ min ago (113+ words) REGN7041 targets CD3, a component of the T-cell receptor complex, and was being developed as an immunomodulatory approach to non-infectious uveitis, a group of inflammatory eye diseases that can cause vision loss. Regeneron listed the candidate in Phase I development for uveitis…...
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit | AAP
1+ hour, 48+ min ago (1106+ words) Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit aap.com.au Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a…...
Pfizer drops IgAN candidate PF-07985631 over benefit-risk assessment
4+ hour, 38+ min ago (190+ words) Pfizer's first-in-human trial of PF-07985631, a biologic in development for IgA nephropathy (IgAN), has been terminated after enrolling 9 participants, according to an update to ClinicalTrials.gov. Pfizer cited an assessment that the candidate's estimated benefit-risk profile was unlikely to be…...